Phase I-II clinical trial of Californium-252. Treatment of stage IB carcinoma of the cervix
Creators
- 1. Univ. of Kentucky Medical Center, Lexington
Description
Intracavitary Californium-252 combined with whole-pelvis photon radiotherapy was tested as the sole form of treatment for 22 patients with Stage IB carcinoma of the cervix. Californium-252 (Cf) is a fast neutron-emitting radioisotope currently being tested in trials of neutron brachytherapy (NT). The outcomes of the treated group of patients were traced for local tumor control, survival, patterns of failure, and complications. The Cf intracavitary therapy combined with whole-pelvis photon radiotherapy resulted in 95% 2-year and 91% 5-year actuarial survival. There were 9% Grade II-III complications by the Stockholm scale and 4% local failures. These results were obtained in an early clinical trial with a group of largely poor-risk patients with tumors of mean diameter of 4.3 cm
Additional details
Publishing Information
- Journal Title
- Cancer (Philadelphia)
- Journal Issue
- no.8
- Series
- Cancer (Philadelphia).
- ISSN
- 0008-543X
- CODEN
- CANCA
INIS
- Country of Publication
- United States
- Country of Input or Organization
- United States
- INIS RN
- 18069483
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CALIFORNIUM 252; CARCINOMAS; FAST NEUTRONS; PATIENTS; PELVIS; RADIOTHERAPY; UTERUS
- Descriptors DEC
- ACTINIDE NUCLEI; ALPHA DECAY RADIOISOTOPES; BARYONS; BODY; BODY AREAS; CALIFORNIUM ISOTOPES; DISEASES; ELEMENTARY PARTICLES; EVEN-EVEN NUCLEI; FEMALE GENITALS; FERMIONS; HADRONS; HEAVY NUCLEI; ISOTOPES; MEDICINE; NEOPLASMS; NEUTRONS; NUCLEI; NUCLEONS; ORGANS; RADIOISOTOPES; SPONTANEOUS FISSION RADIOISOTO; THERAPY; YEARS LIVING RADIOISOTOPES